Trump's action surprised many advocates and researchers in the psychedelic field, given that ibogaine is known to sometimes trigger potentially fatal heart problems.

President Donald Trump signed an executive order Saturday that he said "directs the FDA to expedite their review of certain psychedelics already designated as breakthrough therapy drugs."

President Donald Trump signed an executive order Saturday that he said "directs the FDA to expedite their review of certain psychedelics already designated as breakthrough therapy drugs."

President Donald Trump has directed his administration to speed up reviews of certain psychedelic drugs, including ibogaine.